Supplemental_Data_2_Supplemental_Table_and_Figure_changes_marked_yellow.pdf (1.16 MB)
Supplemental_Data_2_Supplemental_Table_and_Figure_changes_marked_yellow – Supplemental material for Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
journal contribution
posted on 2019-12-31, 13:06 authored by Zhonghan Zhang, Kangmei Zeng, Shen Zhao, Yuanyuan Zhao, Xue Hou, Fan Luo, Feiteng Lu, Yaxiong Zhang, Ting Zhou, Yuxiang Ma, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang, Hongyun ZhaoSupplemental material, Supplemental_Data_2_Supplemental_Table_and_Figure_changes_marked_yellow for Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis by Zhonghan Zhang, Kangmei Zeng, Shen Zhao, Yuanyuan Zhao, Xue Hou, Fan Luo, Feiteng Lu, Yaxiong Zhang, Ting Zhou, Yuxiang Ma, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang and Hongyun Zhao in Therapeutic Advances in Medical Oncology